Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2011, Article ID 490795, 12 pages
http://dx.doi.org/10.4061/2011/490795
Review Article

ADPKD: Prototype of Cardiorenal Syndrome Type 4

1Department of Nephrology, Dialysis and Transplantation, St. Bortolo Hospital, Via Rodolfi 37, 36100 Vicenza, Italy
2IRRIV- International Renal Resarch Institute Vicenza, Vicenza, Italy
3Division of Nephrology, Department of Medical and Surgical Sciences, University of Padova, 35128 Padova, Italy
4Clinical Genetics unit, Department of Pediatrics, University of Padova, 35128 Padova, Italy

Received 23 August 2010; Accepted 26 October 2010

Academic Editor: Mitchell H. Rosner

Copyright © 2011 Grazia Maria Virzì et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. W. Stevenson, A. Nohria, and L. Mielniczuk, “Torrent or torment from the tubules? Challenge of the cardiorenal connection,” Journal of the American College of Cardiology, vol. 45, no. 12, pp. 2004–2007, 2005. View at Publisher · View at Google Scholar
  2. C. Ronco, M. Haapio, A. A. House, N. Anavekar, and R. Bellomo, “Cardiorenal syndrome,” Journal of the American College of Cardiology, vol. 52, no. 19, pp. 1527–1539, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Ronco, C.-Y. Chionh, M. Haapio, N. S. Anavekar, A. House, and R. Bellomo, “The cardiorenal syndrome,” Blood Purification, vol. 27, no. 1, pp. 114–126, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. G. M. Chertow, S.-L. T. Normand, L. R. Silva, and B. J. McNeil, “Survival after acute myocardial infarction in patients with end-stage renal disease: results from the cooperative cardiovascular project,” American Journal of Kidney Diseases, vol. 35, no. 6, pp. 1044–1051, 2000. View at Google Scholar · View at Scopus
  5. C. A. Herzog, “Dismal long-term survival of dialysis patients after acute myocardial infarction: can we alter the outcome?” Nephrology Dialysis Transplantation, vol. 17, no. 1, pp. 7–10, 2002. View at Google Scholar · View at Scopus
  6. A. J. Collins, S. Li, D. T. Gilbertson, J. Liu, S.-C. Chen, and C. A. Herzog, “Chronic kidney disease and cardiovascular disease in the medicare population,” Kidney International, vol. 64, no. 87, supplement, pp. S24–S31, 2003. View at Google Scholar · View at Scopus
  7. C. Ronco, D. N. Cruza, and F. Ronco, “Cardiorenal syndromes,” Current Opinion in Critical Care, vol. 15, no. 5, pp. 384–391, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. B. I. Freedman, J. M. Soucie, A. Chapman, J. Krisher, and W. M. McClellan, “Racial variation in autosomal dominant polycystic kidney disease,” American Journal of Kidney Diseases, vol. 35, no. 1, pp. 35–39, 2000. View at Google Scholar · View at Scopus
  9. S. Feng, G. M. Okenka, C.-X. Bai et al., “Identification and functional characterization of an N-terminal oligomerization domain for polycystin-2,” Journal of Biological Chemistry, vol. 283, no. 42, pp. 28471–28479, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Ecder and R. W. Schrier, “Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease,” Nature Reviews Nephrology, vol. 5, no. 4, pp. 221–228, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. USRDS 2008, August 2010, http://www.usrds.org/adr_2008.htm.
  12. V. E. Torres, P. C. Harris, and Y. Pirson, “Autosomal dominant polycystic kidney disease,” Lancet, vol. 369, no. 9569, pp. 1287–1301, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. G. M. Fick, A. M. Johnson, W. S. Hammond, and P. A. Gabow, “Causes of death in autosomal dominant polycystic kidney disease,” Journal of the American Society of Nephrology, vol. 5, no. 12, pp. 2048–2056, 1995. View at Google Scholar · View at Scopus
  14. S. Rossetti and P. C. Harris, “Genotype-phenotype correlations in autosomal dominant and autosomal recessive polycystic kidney disease,” Journal of the American Society of Nephrology, vol. 18, no. 5, pp. 1374–1380, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Igarashi and S. Somlo, “Genetics and pathogenesis of polycystic kidney disease,” Journal of the American Society of Nephrology, vol. 13, no. 9, pp. 2384–2398, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Mochizuki, G. Wu, T. Hayashi et al., “PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein,” Science, vol. 272, no. 5266, pp. 1339–1342, 1996. View at Google Scholar · View at Scopus
  17. Y. Pei, A. D. Paterson, K. R. W. et al., “Bilineal disease and trans-heterozygotes in autosomal dominant polycystic kidney disease,” American Journal of Human Genetics, vol. 68, no. 2, pp. 355–363, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. M. D. Griffin, V. E. Torres, J. P. Grande, and R. Kumar, “Vascular expression of polycystin,” Journal of the American Society of Nephrology, vol. 8, no. 4, pp. 616–626, 1997. View at Google Scholar · View at Scopus
  19. S. Rossetti, D. Chauveau, V. Kubly et al., “Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype,” Lancet, vol. 361, no. 9376, pp. 2196–2201, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Qian, A. Boletta, A. K. Bhunia et al., “Cleavage of polycystin-1 requires the receptor for egg jelly domain and is disrupted by human autosomal-dominant polycystic kidney disease 1-associated mutations,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 26, pp. 16981–16986, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. W. M. Bennett, “Autosomal dominant polycystic kidney disease: 2009 update for internists,” Korean Journal of Internal Medicine, vol. 24, no. 3, pp. 165–168, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. P. D. Wilson, “Polycystic kidney disease,” New England Journal of Medicine, vol. 350, no. 2, pp. 151–164, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. P. C. Harris and S. Rossetti, “Determinants of renal disease variability in ADPKD,” Advances in Chronic Kidney Disease, vol. 17, no. 2, pp. 131–139, 2010. View at Publisher · View at Google Scholar
  24. N. Hateboer, M. A.V. Dijk, N. Bogdanova et al., “Comparison of phonotypes of polycystic kidney disease types 1 and 2,” Lancet, vol. 353, no. 9147, pp. 103–107, 1999. View at Publisher · View at Google Scholar
  25. J. J. Grantham, “Clinical practice. Autosomal dominant polycystic kidney disease,” New England Journal of Medicine, vol. 359, no. 14, pp. 1477–1485, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. W. E. Braun, “Autosomal dominant polycystic kidney disease: emerging concepts of pathogenesis and new treatments,” Cleveland Clinic Journal of Medicine, vol. 76, no. 2, pp. 97–104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Timio, C. Monarca, S. Pede, S. Gentili, C. Verdura, and S. Lolli, “The spectrum of cardiovascular abnormalities in autosomal dominant polycystic kidney disease: a 10-year follow-up in a five-generation kindred,” Clinical Nephrology, vol. 37, no. 5, pp. 245–251, 1992. View at Google Scholar · View at Scopus
  28. D. D. Ivy, E. M. Shaffer, A. M. Johnson, W. J. Kimberling, A. Dobin, and P. A. Gabow, “Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease,” Journal of the American Society of Nephrology, vol. 5, no. 12, pp. 2032–2036, 1995. View at Google Scholar · View at Scopus
  29. O. Kocaman, H. Oflaz, E. Yekeler et al., “Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease,” American Journal of Kidney Diseases, vol. 43, no. 5, pp. 854–860, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Bichet, D. Peters, A. J. Patel, P. Delmas, and E. Honoré, “Cardiovascular polycystins: insights from autosomal dominant polycystic kidney disease and transgenic animal models,” Trends in Cardiovascular Medicine, vol. 16, no. 8, pp. 292–298, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Stypmann, M. A. Engelen, S. Orwat et al., “Cardiovascular characterization of Pkd2+/LacZ mice, an animal model for the autosomal dominant polycystic kidney disease type 2 (ADPKD2),” International Journal of Cardiology, vol. 120, no. 2, pp. 158–166, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Kim, I. Drummond, O. Ibraghimov-Beskrovnaya, K. Klinger, and M. A. Arnaout, “Polycystin 1 is required for the structural integrity of blood vessels,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 4, pp. 1731–1736, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Boulter, S. Mulroy, S. Webb, S. Fleming, K. Brindle, and R. Sandford, “Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 21, pp. 12174–12179, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Kurbegovic, O. Côté, M. Couillard, C. J. Ward, P. C. Harris, and M. Trudel, “Pkd1 transgenic mice: adult model of polycystic kidney disease with extrarenal and renal phenotypes,” Human Molecular Genetics, vol. 19, no. 7, pp. 1174–1189, 2010. View at Publisher · View at Google Scholar
  35. T. Ecder and R. W. Schrier, “Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects,” Journal of the American Society of Nephrology, vol. 12, no. 1, pp. 194–200, 2001. View at Google Scholar · View at Scopus
  36. A. B. Chapman, A. M. Johnson, S. Rainguet, K. Hossack, P. Gabow, and R. W. Schrier, “Left ventricular hypertrophy in autosomal dominant polycystic kidney disease,” Journal of the American Society of Nephrology, vol. 8, no. 8, pp. 1292–1297, 1997. View at Google Scholar · View at Scopus
  37. P. A. Gabow, A. M. Johnson, W. D. Kaehny et al., “Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease,” Kidney International, vol. 41, no. 5, pp. 1311–1319, 1992. View at Google Scholar · View at Scopus
  38. A. Remppis and E. Ritz, “Cardiac problems in the dialysis patient: beyond coronary disease,” Seminars in Dialysis, vol. 21, no. 4, pp. 319–325, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. P. A. Gabow, D. W. Ikle, and J. H. Holmes, “Polycystic kidney disease: prospective analysis of nonazotemic patients and family members,” Annals of Internal Medicine, vol. 101, no. 2, pp. 238–247, 1984. View at Google Scholar · View at Scopus
  40. E. Valvo, L. Gammaro, N. Tessitore et al., “Hypertension of polycystic kidney disease: mechanisms and hemodynamic alterations,” American Journal of Nephrology, vol. 5, no. 3, pp. 176–181, 1985. View at Google Scholar
  41. A. B. Chapman, L. M. Guay-Woodford, J. J. Grantham et al., “Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The consortium for radiologic imaging studies of polycystic kidney disease (CRISP) cohort,” Kidney International, vol. 64, no. 3, pp. 1035–1045, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. P. A. Gabow, “Medical progress: autosomal dominant polycystic kidney disease,” New England Journal of Medicine, vol. 329, no. 5, pp. 332–342, 1993. View at Publisher · View at Google Scholar · View at Scopus
  43. A. B. Chapman, K. Stepniakowski, and F. Rahbari-Oskoui, “Hypertension in autosomal dominant polycystic kidney disease,” Advances in Chronic Kidney Disease, vol. 17, no. 2, pp. 153–163, 2010. View at Publisher · View at Google Scholar
  44. M. Loghman-Adham, C. E. Soto, T. Inagami, and L. Cassis, “The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease,” American Journal of Physiology, vol. 287, no. 4, pp. F775–F788, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. V. E. Torres, D. M. Wilson, J. C. Burnett Jr., C. M. Johnson, and K. P. Offord, “Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease,” Mayo Clinic Proceedings, vol. 66, no. 10, pp. 1010–1017, 1991. View at Google Scholar · View at Scopus
  46. A. B. Chapman, A. M. Johnson, P. A. Gabow, and R. W. Schrier, “Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease,” Journal of the American Society of Nephrology, vol. 5, no. 6, pp. 1349–1354, 1994. View at Google Scholar · View at Scopus
  47. A. B. Chapman, A. Johnson, P. A. Gabow, and R. W. Schrier, “The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease,” New England Journal of Medicine, vol. 323, no. 16, pp. 1091–1096, 1990. View at Google Scholar · View at Scopus
  48. I. H. H. T. Klein, G. Ligtenberg, P. L. Oey, H. A. Koomans, and P. J. Blankestijn, “Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension,” Journal of the American Society of Nephrology, vol. 12, no. 11, pp. 2427–2433, 2001. View at Google Scholar · View at Scopus
  49. T. W. Doulton, A. K. Saggar-Malik, F. J. He et al., “The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-angiotensin system in autosomal-dominant polycystic kidney disease patients,” Journal of Hypertension, vol. 24, no. 5, pp. 939–945, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Martinez-Vea, F. A. Valero, A. Bardaji et al., “Left ventricular hypertrophy in hypertensive patients with autosomal dominant polycystic kidney disease: Influence of blood pressure and humoral and neurohormonal factors,” American Journal of Nephrology, vol. 20, no. 3, pp. 193–200, 2000. View at Google Scholar · View at Scopus
  51. M.-L. Gross and E. Ritz, “Hypertrophy and fibrosis in the cardiomyopathy of uremia—beyond coronary heart disease,” Seminars in Dialysis, vol. 21, no. 4, pp. 308–318, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Huston III, V. E. Torres, P. P. Sulivan, K. P. Offord, and D. O. Wiebers, “Value of magnetic resonance angiography for the detection of intracranial aneurysms in autosomal dominant polycystic kidney disease,” Journal of the American Society of Nephrology, vol. 3, no. 12, pp. 1871–1877, 1993. View at Google Scholar · View at Scopus
  53. M. M. Belz, R. L. Hughes, W. D. Kaehny et al., “Familial clustering of ruptured intracranial aneurysms in autosomal dominant polycystic kidney disease,” American Journal of Kidney Diseases, vol. 38, no. 4, pp. 770–776, 2001. View at Google Scholar · View at Scopus
  54. E. Meijer, W. E. Boertien, F. L. Nauta et al., “Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis,” American Journal of Kidney Diseases, vol. 56, no. 5, pp. 883–895, 2010. View at Publisher · View at Google Scholar
  55. D. Bolignano, G. Coppolino, S. Campo et al., “Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease,” American Journal of Nephrology, vol. 27, no. 4, pp. 373–378, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. J. A. Casal, J. Hermida, X. M. Lens, and J. C. Tutor, “A comparative study of three kidney biomarker tests in autosomal-dominant polycystic kidney disease,” Kidney International, vol. 68, no. 3, pp. 948–954, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Wong, L. Vivian, G. Weiler, and G. Filler, “Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease,” American Journal of Kidney Diseases, vol. 43, no. 4, pp. 624–628, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. D. N. Cruz, S. Soni, L. Slavin, C. Ronco, and A. Maisel, “Biomarkers of cardiac and kidney dysfunction in cardiorenal syndromes,” Contributions to Nephrology, vol. 165, pp. 83–92, 2010. View at Publisher · View at Google Scholar
  59. S. Manzano-Fernández, M. Boronat-Garcia, M. D. Albaladejo-Otón et al., “Complementary prognostic value of cystatin C, N-terminal Pro-B-type natriuretic peptide and cardiac troponin T in patients with acute heart failure,” American Journal of Cardiology, vol. 103, no. 12, pp. 1753–1759, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. Y. Iwanaga and S. Miyazaki, “Heart failure, chronic kidney disease, and biomarkers—an integrated viewpoint,” Circulation Journal, vol. 74, no. 7, pp. 1275–1282, 2010. View at Google Scholar
  61. A. Martinez-Vea, C. Gutierrez, A. Bardají et al., “Microalbuminuria in normotensive patients with autosomal-dominant polycystic kidney disease,” Scandinavian Journal of Urology and Nephrology, vol. 32, no. 5, pp. 356–359, 1998. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Martinez-Vea, A. Bardají, C. Gutierrez et al., “Exercise blood pressure, cardiac structure, and diastolic function in young normotensive patients with polycystic kidney disease: a prehypertensive state,” American Journal of Kidney Diseases, vol. 44, no. 2, pp. 216–223, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. L. B. Daniels and A. S. Maisel, “Natriuretic peptides,” Journal of the American College of Cardiology, vol. 50, no. 25, pp. 2357–2368, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. C. R. DeFilippi, J. C. Fink, C. M. Nass, H. Chen, and R. Christenson, “N-Terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis,” American Journal of Kidney Diseases, vol. 46, no. 1, pp. 35–44, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. S. J. Carr, S. Bavanandan, B. Fentum, and L. Ng, “Prognostic potential of brain natriuretic peptide (BNP) in predialysis chronic kidney disease patients,” Clinical Science, vol. 109, no. 1, pp. 75–82, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. P. A. McCullough and K. R. Sandberg, “Sorting out the evidence on natriuretic peptides,” Reviews in Cardiovascular Medicine, vol. 4, supplement 4, pp. S13–S19, 2003. View at Google Scholar · View at Scopus
  67. D. S. Ooi, D. Zimmerman, J. Graham, and G. A. Wells, “Cardiac troponin T predicts long-term outcomes in hemodialysis patients,” Clinical Chemistry, vol. 47, no. 3, pp. 412–417, 2001. View at Google Scholar · View at Scopus
  68. J. Dierkes, U. Domröse, S. Westphal et al., “Cardiac troponin T predicts mortality in patients end-stage renal disease,” Circulation, vol. 102, no. 16, pp. 1964–1969, 2000. View at Google Scholar · View at Scopus
  69. F. Mallamaci, C. Zoccali, S. Parlongo et al., “Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients,” American Journal of Kidney Diseases, vol. 40, no. 1, pp. 68–75, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. G. N. I. Wood, B. Keevil, J. Gupta et al., “Serum troponin T measurement in patients with chronic renal impairment predicts survival and vascular disease: a 2 year prospective study,” Nephrology Dialysis Transplantation, vol. 18, no. 8, pp. 1610–1615, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. T. Tsutamoto, C. Kawahara, M. Yamaji et al., “Relationship between renal function and serum cardiac troponin T in patients with chronic heart failure,” European Journal of Heart Failure, vol. 11, no. 7, pp. 653–658, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. R. L. Young and K.-B. Lee, “Reliability of magnetic resonance imaging for measuring the volumetric indices in autosomal-dominant polycystic kidney disease: correlation with hypertension and renal function,” Nephron Clinical Practice, vol. 103, no. 4, pp. c173–c180, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. Y. Pei, J. Obaji, A. Dupuis et al., “Unified criteria for ultrasonographic diagnosis of ADPKD,” Journal of the American Society of Nephrology, vol. 20, no. 1, pp. 205–212, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. P. C. Harris and S. Rossetti, “Molecular diagnostics for autosomal dominant polycystic kidney disease,” Nature Reviews Nephrology, vol. 6, no. 4, pp. 197–206, 2010. View at Publisher · View at Google Scholar
  75. B. F. King, J. E. Reed, E. J. Bergstralh, P. F. Sheedy II, and V. E. Torres, “Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease,” Journal of the American Society of Nephrology, vol. 11, no. 8, pp. 1505–1511, 2000. View at Google Scholar · View at Scopus
  76. K. T. Bae, C. Tao, F. Zhu et al., “MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 4, pp. 719–725, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. A. D. Waggoner and S. M. Bierig, “Tissue Doppler imaging: a useful echocardiographic method for the cardiac sonographer to assess systolic and diastolic ventricular function,” Journal of the American Society of Echocardiography, vol. 14, no. 12, pp. 1143–1152, 2001. View at Publisher · View at Google Scholar · View at Scopus
  78. W. Burke, “Genetic testing,” The New England Journal of Medicine, vol. 347, no. 23, pp. 1867–1875, 2002. View at Google Scholar · View at Scopus
  79. M. Taylor, A. M. Johnson, M. Tison, P. Fain, and R. W. Schrier, “Earlier diagnosis of autosomal dominant polycystic kidney disease: importance of family history and implications for cardiovascular and renal complications,” American Journal of Kidney Diseases, vol. 46, no. 3, pp. 415–423, 2005. View at Publisher · View at Google Scholar · View at Scopus
  80. R. W. Schrier, K. K. McFann, and A. M. Johnson, “Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease,” Kidney International, vol. 63, no. 2, pp. 678–685, 2003. View at Publisher · View at Google Scholar · View at Scopus
  81. R. D. Perrone and D. C. Miskulin, “Hypertension in individuals at risk for autosomal dominant polycystic kidney disease: to screen or not to screen?” American Journal of Kidney Diseases, vol. 46, no. 3, pp. 557–559, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. H. Krum, P. Iyngkaran, and S. Lekawanvijit, “Pharmacologic management of the cardiorenal syndrome in heart failure,” Current Heart Failure Reports, vol. 6, no. 2, pp. 105–111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. R. Schrier, K. McFann, A. Johnson et al., “Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study,” Journal of the American Society of Nephrology, vol. 13, no. 7, pp. 1733–1739, 2002. View at Publisher · View at Google Scholar · View at Scopus
  84. A. S. Levey, M. V. Rocco, S. Anderson et al., “K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease,” American Journal of Kidney Diseases, vol. 43, no. 5, supplement 1, pp. S1–S290, 2004. View at Google Scholar · View at Scopus
  85. R. W. Schrier, “Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease,” Journal of the American Society of Nephrology, vol. 20, no. 9, pp. 1888–1893, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. T. H. Jafar, P. C. Stark, C. H. Schmid et al., “The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease,” Kidney International, vol. 67, no. 1, pp. 265–271, 2005. View at Publisher · View at Google Scholar · View at Scopus
  87. K. Nutahara, E. Higashihara, S. Horie et al., “Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease,” Nephron Clinical Practice, vol. 99, no. 1, pp. c18–c23, 2005. View at Publisher · View at Google Scholar · View at Scopus
  88. T. Ecder, C. L. Edelstein, G. M. Fick-Brosnahan et al., “Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease,” American Journal of Nephrology, vol. 21, no. 2, pp. 98–103, 2001. View at Publisher · View at Google Scholar · View at Scopus
  89. V. E. Torres, “Treatment strategies and clinical trial design in ADPKD,” Advances in Chronic Kidney Disease, vol. 17, no. 2, pp. 190–204, 2010. View at Publisher · View at Google Scholar
  90. V. E. Torres, X. Wang, Q. Qian, S. Somlo, P. C. Harris, and V. H. Gattone II, “Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease,” Nature Medicine, vol. 10, no. 4, pp. 363–364, 2004. View at Publisher · View at Google Scholar · View at Scopus
  91. V. E. Torres, “Role of vasopressin antagonists,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 4, pp. 1212–1218, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Caroli, L. Antiga, M. Cafaro et al., “Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 5, pp. 783–789, 2010. View at Publisher · View at Google Scholar
  93. M. C. Hogan, T. V. Masyuk, L. J. Page et al., “Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease,” Journal of the American Society of Nephrology, vol. 21, no. 6, pp. 1052–1061, 2010. View at Publisher · View at Google Scholar
  94. L. van Keimpema, F. Nevens, R. Vanslembrouck et al., “Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial,” Gastroenterology, vol. 137, no. 5, article e1-2, pp. 1661–1668, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. P. R. Wahl, A. L. Serra, M. Le Hir, K. D. Molle, M. N. Hall, and R. P. Wüthrich, “Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD),” Nephrology Dialysis Transplantation, vol. 21, no. 3, pp. 598–604, 2006. View at Publisher · View at Google Scholar · View at Scopus
  96. Q. Qian, H. Du, B. F. King et al., “Sirolimus reduces polycystic liver volume in ADPKD patients,” Journal of the American Society of Nephrology, vol. 19, no. 3, pp. 631–638, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. R. G. Fassett, J. S. Coombes, D. Packham, K. F. Fairley, and P. Kincaid-Smith, “Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease,” Scandinavian Journal of Urology and Nephrology, vol. 44, no. 1, pp. 56–61, 2010. View at Publisher · View at Google Scholar
  98. F. A. Belibi and C. L. Edelstein, “Novel targets for the treatment of autosomal dominant polycystic kidney disease,” Expert Opinion on Investigational Drugs, vol. 19, no. 3, pp. 315–328, 2010. View at Publisher · View at Google Scholar
  99. S. Namli, H. Oflaz, F. Turgut et al., “Improvement of endothelial dysfunction with simvastatin in patients with autosomal dominant polycystic kidney disease,” Renal Failure, vol. 29, no. 1, pp. 55–59, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. Clinical Trials., October 2010, www.clinicalTrials.gov.
  101. B. F. King, V. E. Torres, M. E. Brummer et al., “Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease,” Kidney International, vol. 64, no. 6, pp. 2214–2221, 2003. View at Publisher · View at Google Scholar · View at Scopus